 |
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2008, vol. 14, book 1
Subject Collection: Medicine
Page: 48-50
DOI: 10.5272/jimab.14-1-2010.48
Online date: September 24, 2008
J of IMAB 2008; 14(1):48-50
IRINOTECAN, FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL CANCER
Deyan Davidov
,
Department of chemotherapy, Oncological center, Medical University, Pleven,Bulgaria
ABSTRACT:
Background: Irinotecan
is a topoisomerase I inhibitor that prolongs survival as second- line
therapy in patients with metastatic colorectal cancer, treated with Fluorouracil
and Leucovorin only.
Aim: The aim of this study was to
evaluate the efficacy and toxicity of the combination Irinotecan, Fluorouracil
and Leucovorin.
Methods: In the period 2006- 2007 34
patients with metastatic colorectal cancer entered the study. The treatment
schedule consists of Irinotecan 180 mg/m2 day 1, Fluorouracil 400 mg/m2
day 1 and 2 and Leucovorin 200 mg/m2 day 1 and 2 every 14 days.
Results: Overall response rate was 36,7% with three complete remissions. Median
survival was 20,3 months. Diarrhea, vomiting and mucositis were most common
side effects.
Conclusions: That data suggest that the
addition of Irinotecan to Fluorouracil and Leucovorin will offer opportunity
to treat patients with metastatic colorectal cancer.
Key words: Irinotecan, Colorectal cancer, Treatment, Survival.
- Download FULL TEXT (PDF - 262 KB)
Please cite this article as:
Davidov D. IRINOTECAN, FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL CANCER. J of IMAB 2008; 14(1):48-50. DOI: 10.5272/jimab.14-1-2010.48
REFERENCES:
1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et all, Cancer Statistics, 2004. CA Cancer J Clin. 2004 Jan-Feb;54(1):8–29. [PubMed]
2. Glimelius B, Hofman K, Graf W, Pahlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Cancer 1994 Feb 1;73(3):556–562. [PubMed]
3. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer 1997 Oct 1;80(7):1179–1187. [PubMed]
4. Meta-analysis Group in Cancer. Efficacy of IV continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998 Jan;16(1):301–308. [PubMed]
5. Pommier Y, Tanizava A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv Pharmacol. 1994; 29B; 73-92. ]PubMed]
6. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998 Oct 31;352(9138):1407-1412. doi:10.1016/S0140-6736(98)03085-2 CrossRef] [PubMed]
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first- line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000 Mar 25;355(9209):1041-7. doi:10.1016/S0140-6736(00)02034-1 CrossRef] [PubMed]
8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1);207-214 [PubMed]
9. Brimdage MD, Pater JL, Zee B: Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst. 1993 Jul 21;85(14)1138-1148. [PubMed]
10. Kaplan EL, Meyer P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959; 53; 457- 481
11. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004 Jan 15;22(2):229-237; Epub 2003 Dec 2. DOI: 10.1200/JCO.2004.05.113 CrossRef] [PubMed]
12. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et all: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxalplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004 Jan 1;22(1):23-30. Epub 2003 Dec 9. DOI: 10.1200/JCO.2004.09.046 CrossRef] [PubMed]